Dr. Gerald S. Lipshutz, MD, MS, received his medical degree from the University of California, Los Angeles (UCLA) School of Medicine and completed his postgraduate training at the University of California, San Francisco School of Medicine. He is currently a Professor in the Departments of Surgery and Molecular and Medical Pharmacology at UCLA. Dr. Lipshutz is also a member of the UCLA Intellectual and Developmental Disabilities Research Center and the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, where he holds the Goldwyn Chair.
Dr. Lipshutz’s research focuses on developing innovative gene and cell therapies for single-gene metabolic disorders affecting the liver. He has been an invited participant in numerous National Institutes of Health (NIH) conferences and has served as a grant reviewer for both the Wellcome Trust in the United Kingdom and the NIH. He recently completed four years as a standing member of the NIH Genetic Disorders and Developmental Disabilities (GDD) Study Section.
An accomplished researcher and educator, Dr. Lipshutz has authored more than 80 peer-reviewed scientific publications. He also serves on the editorial boards of Molecular Therapy, Molecular Therapy: Methods & Clinical Development, and Gene Therapy. In addition, he is an active member of several professional organizations focused on surgery, transplantation, gene therapy, and metabolic disorders, including the American Society of Gene & Cell Therapy (ASGCT) and the Society for Inherited Metabolic Disorders (SIMD).
As Principal Investigator of the UCLA Lipshutz Hepatic Regenerative Medicine Laboratory, Dr. Lipshutz leads research into regenerative medicine approaches for the treatment of urea cycle disorders, including arginase deficiency and carbamoyl phosphate synthetase deficiency, as well as creatine deficiency disorders. His work aims to develop therapies that could one day replace liver transplantation for patients with single-enzyme metabolic diseases. He is also dedicated to advancing the understanding of the neurological effects of arginase deficiency and hyperargininemia.
Dr. Lipshutz currently serves as Principal Investigator on multiple NIH-funded, California Institute for Regenerative Medicine (CIRM)-funded, and industry-sponsored studies focused on the development of next-generation gene therapies for rare metabolic disorders.